

NOW ENROLLING IN RENAL CELL CARCINOMA



PHASE 3 (NCT03729245)

PIVOT-09: Bempegaldesleukin with nivolumab in patients with advanced renal cell carcinoma (RCC)

A randomized study of bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) compared with the Investigator's choice of tyrosine kinase inhibitor therapy (either sunitinib or cabozantinib) for previously untreated advanced RCC¹

ENROLL NOW


Scan here to find out more about this clinical study at ClinicalTrials.gov



POPULATION

- Previously untreated advanced RCC
- Any IMDC prognostic score
- Tumor tissue available for PD-L1 testing

N~600



BEMPEG + NIVO

Investigator's choice of sunitinib or cabozantinib

CO-PRIMARY ENDPOINTS

- Objective response rate
- Overall survival

KEY SECONDARY ENDPOINT

- Progression-free survival

Bempegaldesleukin is an investigational first-in-class CD122-preferential IL-2-pathway agonist²

Nivolumab is a PD-1 blocking antibody³

^aRandomization is stratified by IMDC prognostic score: favorable (0) vs intermediate (1 or 2) vs poor (3–6) and tyrosine kinase inhibitor choice: either sunitinib or cabozantinib.

BEMPEG, bempegaldesleukin (NKTR-214); IL-2, interleukin-2; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NIVO, nivolumab; PD-1, programmed death-1; PD-L1, programmed death-ligand 1.

1. ClinicalTrials.gov. NCT03729245. <https://clinicaltrials.gov/ct2/show/NCT03729245>. Accessed May 1, 2020. 2. Charych DH, et al. *Clin Cancer Res* 2016;22:680–690.

3. Opdivo (nivolumab) Prescribing Information (Princeton, NJ: Bristol Myers Squibb; revised: May 2020).

CLINICAL TRIALS WITH BEMPEGALDESLEUKIN AND NIVOLUMAB ARE NOW ENROLLING


NEKTAR

 Bristol Myers Squibb™

Bempegaldesleukin (BEMPEG; NKTR-214) in combination with nivolumab (NIVO) leverage two immuno-oncology pathways with the aim of addressing the unmet needs of patients living with cancer

FIND OUT MORE

Scan here to discover more about BEMPEG at Nektar.com



BEMPEG, bempegaldesleukin (NKTR-214); NIVO, nivolumab.

FOR EDUCATIONAL PURPOSES ONLY.

This compound and the combination of agents and their uses have not been approved.

Nektar Therapeutics, 455 Mission Bay Boulevard, South San Francisco, California 94158. Copyright Nektar Therapeutics © 2020. All rights reserved.